Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

FOLIC ACID IMPURITY D CRS (15MG)

FOLIC ACID IMPURITY D CRS (15MG)

119-24-4

DISCOVER
AMYLMETACRESOL CRS (300 MG)

AMYLMETACRESOL CRS (300 MG)

1300-94-3

DISCOVER
Amylmetacresol for peak identification CRS, 10mg

Amylmetacresol for peak identification CRS, 10mg

1300-94-3

DISCOVER
AZATHIOPRINE IMPURITY G CRS (5 MG)

AZATHIOPRINE IMPURITY G CRS (5 MG)

5581-52-2

DISCOVER
TROPICAMIDE IMPURITY C CRS (15 MG)

TROPICAMIDE IMPURITY C CRS (15 MG)

529-64-6

DISCOVER
TROPICAMIDE IMPURITY D CRS - * DRUG PRECURSOR (PHENYLACETIC

TROPICAMIDE IMPURITY D CRS - * DRUG PRECURSOR (PHENYLACETIC

103-82-2

DISCOVER
ENTACAPONE CRS (160 MG)

ENTACAPONE CRS (160 MG)

130929-57-6

DISCOVER
ENTACAPONE IMPURITY A CRS (10MG)

ENTACAPONE IMPURITY A CRS (10MG)

NA

DISCOVER
PHENTOLAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

PHENTOLAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

65-28-1

DISCOVER
MEROPENEM  TRIHYDRATE CRS (110 MG)

MEROPENEM TRIHYDRATE CRS (110 MG)

119478-56-7

DISCOVER
LEVETIRACETAM CRS (120 MG)

LEVETIRACETAM CRS (120 MG)

102767-28-2

DISCOVER
LEVETIRACETAM IMPURITY A CRS (10 MG)

LEVETIRACETAM IMPURITY A CRS (10 MG)

NA

DISCOVER